YK
Publicaties op Oncologisch.com
Cemiplimab Monotherapy for Eerstelijns Behandeling of Patients with Gevorderd NSCLC With PD-L1 Expression of 50% or H...
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positi...
Cemiplimab mono en cemiplimab beyond progression plus chemo bij NSCLC: EMPOWER-Lung 1 definitief